Mizoribine for crescentic glomerulonephritis with sarcoidosis: effectiveness not only for urinalysis abnormalities but also for hilar lymph node enlargement

References

• Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153–65.
   PubMed Web of Science ®Google Scholar
• Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis. 2006;48:856–70.
   PubMed Web of Science ®Google Scholar
• Gobel U, Kettritz R, Schneider W, Luft F. The protean face of renal sarcoidosis. J Am Soc Nephrol. 2001;12:616–23.
   PubMed Web of Science ®Google Scholar
• van Uum SH, Cooreman MP, Assmann KJ, Wetzels JF. A 58-year-old man with sarcoidosis complicated by focal crescentic glomerulonephritis. Nephrol Dial Transpl. 1997;12:2703–7.
   PubMed Web of Science ®Google Scholar
• Auinger M, Irsigler K, Breiteneder S, Ulrich W. Normocalcaemic hepatorenal sarcoidosis with crescentic glomerulonephritis. Nephrol Dial Transpl. 1997;12:1474–7.
   PubMed Web of Science ®Google Scholar
• Sonda K, Takahashi K, Tanabe K, Funchinoue S, Hayasaka Y, Kawaguchi H, et al. Clinical pharmacokinetic study of mizoribine in renal transplantation patients. Transpl Proc. 1996;28:3643–8.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y. Mizoribine: a new approach in the treatment of renal disease. Clin Dev Immunol. 2009;2009:681482.
   PubMedGoogle Scholar
• Hirayama K, Kobayashi M, Hashimoto Y, Usui J, Shimizu Y, Hirayama A, et al. Treatment with the purine synthesis inhibitor mizoribine for ANCA-associated renal vasculitis. Am J Kidney Dis. 2004;44:57–63.
   PubMed Web of Science ®Google Scholar
• Ho LP, Urban BC, Thickett DR, Davies RJO, McMichael AJ. Deficiency of a subset of T cells with immunoregulatory prop-erties in sarcoidosis. Lancet. 2005;365:1062–72.
   Google Scholar
• Miyagaki T, Asano Y, Shibata S, Ohno Y, Tsunemi Y, Saeki H, et al. The development of Thl-mediated sarcoidosis improves the clinical course of Th2-mediated atopic dermatitis. Mod Rheu-matol. 2011;21:406–9.
   PubMed Web of Science ®Google Scholar
• Tipping PG, Kitching AR. Glomerulonephritis, Th 1 and Th2: what's new? Clin Exp Immunol. 2005;142:207-15.
   Google Scholar
• Wilde B, van Paassen P, Witzke 0, Tervaert JW. New patho-physiological insights and treatment of ANCA-associated vasculitis. Kidney Int. 2011;79:599–612.
   Google Scholar
• Gomez-Puerta JA, Bosch X. Anti-neutrophil cytoplasmic anti-body pathogenesis in small-vessel vasculitis: an update. Am J Pathol. 2009;175:1790–8.
   Google Scholar
• Franssen CF, Stegeman CA, Oost-Kort WW, Kallenberg CG, Limburg PC, Tiebosch A, et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomeru-lonephritis. J Am Soc Nephrol. 1998;9:1915–23.
   Google Scholar
• Nakabayashi K. Slowly progressive, not rapidly progressive, MPO-ANCA positive glomerulonephritis and its characteristics. Intern Med. 2002;41:418–9.
   PubMed Web of Science ®Google Scholar
• Aoyama T, Shimizu T, Matsuo T, Sakamoto H, Kamata K, Higashihara M, et al. MPO-ANCA-positive slowly progressive glomerulonephritis with focal tuft necrosis and crescents. Intern Med. 2002;41:458–62.
   PubMed Web of Science ®Google Scholar
• Yoshida M. Antineutrophil cytoplasmic antibody (ANCA) asso-ciated vasculitis: from molecular analysis to bedside. Intern Med. 2002;41:47–9.
   PubMed Web of Science ®Google Scholar
• Altschuler EL. The first case of sarcoidosis treated with mycophen-olate mofetil. Br J Dermatol. 2003;149:442; discussion 442–443.
   Google Scholar
• Moudgil A, Przygodzki RM, Kher KK. Successful steroid-spar-ing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol. 2006;21:281–5.
   Google Scholar
• Yumura W, Suganuma S, Uchida K, Moriyama T, Otsubo S, Takei T, et al. Effects of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005;64: 28–34.
   PubMed Web of Science ®Google Scholar
• Kuroda T, Kobayashi D, Sato H, Oyanagi A, Wada Y, Murakami S, et al. Mizoribine therapy in a patient with lupus nephritis: the association between mizoribine concentration and peritoneal dialysis. Mod Rheumatol. 2010;20:296–300.
   PubMed Web of Science ®Google Scholar
• Kaneko T, Hirama A, Ueda K, Fujino T, Utsumi K, lino Y, et al. Methylprednisolone pulse therapy combined with mizoribine following tonsillectomy for immunoglobulin A nephropathy: clinical remission rate, steroid sparing effect, and maintenance of renal function. Clin Exp Nephrol. 2011;15:73–8.
   PubMed Web of Science ®Google Scholar
• Ito S, Harada T, Nakamura T, Imagawa T, Nagahama K, Sasaki T, et al. Mizoribine for renal sarcoidosis: effective steroid tapering and prevention of recurrence. Pediatr Nephrol. 2009;24:411–4.
   PubMed Web of Science ®Google Scholar